177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Clinical trial NCT05475210 · UNKNOWN
Trial details
- NCT number
- NCT05475210
- Sponsor
- Molecular Targeting Technologies, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-18
- Primary completion
- 2024-12-31
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.